Influence of gut bacteria on type 2 diabetes: Mechanisms and therapeutic strategy

被引：8

作者：

Wen, Xue ^{[1
]}

Qi, Lu-Ming ^{[1
]}

Zhao, Kui ^{[2
]}

机构：

[1] Chengdu Univ Tradit Chinese Med, Coll Hlth & Rehabil, Chengdu 610000, Sichuan, Peoples R China

[2] Southwest Forestry Univ, Coll Mat & Chem Engn, 300 White Dragon Temple, Kunming 650224, Yunnan, Peoples R China

来源：

WORLD JOURNAL OF DIABETES | 2025年 / 16卷 / 01期

关键词：

Type; 2; diabetes; Intestinal microbiome; Intestinal axis; Biological pathways; Treatment; Short-chain fatty acids; P-CRESYL SULFATE; INSULIN SENSITIVITY; INDIGENOUS BACTERIA; MICROBIOTA; MODULATION; PROBIOTICS; RECEPTOR; OBESITY;

D O I：

10.4239/wjd.v16.i1.100376

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The onset and progression of type 2 diabetes mellitus (T2DM) are strongly associated with imbalances in gut bacteria, making the gut microbiome a new potential therapeutic focus. This commentary examines the recent publication in World Journal of Diabetes. The article explores the association between T2DM and gut microbiota, with a focus on the pathophysiological changes related to dysbiosis. It proposes innovative microbiome-targeted therapeutic strategies and evaluates the challenges and future directions of such approaches. This editorial summarizes the key points of their discussion of the role of the gut microbiome in T2DM and elaborates on the influence of specific gut microbial species on the disease through the host-microbiota metabolic axis. It provides new insights for future research on gut-microbiota-based interventions for T2DM.

引用

页数：8

共 50 条

[31] Mechanistic insights into postbiotics as therapeutic agents in type 2 diabetes management [J].

Ebadpour, Negar ;

Faraji, Navid ;

Abavisani, Mohammad ;

Karav, Sercan ;

Sahebkar, Amirhossein .

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,

[32] Type 2 Diabetes and Bacteremia [J].

Sato, Junko ;

Kanazawa, Akio ;

Watada, Hirotaka .

ANNALS OF NUTRITION AND METABOLISM, 2017, 71 :17-22

[33] Pharmacological induction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes [J].

Zamora, Monica ;

Pardo, Rosario ;

Villena, Josep A. .

BIOCHEMICAL PHARMACOLOGY, 2015, 98 (01) :16-28

[34] Role of PPARγ in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential [J].

Yang, Jichun ;

Zhang, Dongjuan ;

Li, Jing ;

Zhang, Xiaoyan ;

Fan, Fenling ;

Guan, Youfei .

CLINICAL SCIENCE, 2009, 116 (1-2) :17-26

[35] Gut microbiome research: Revealing the pathological mechanisms and treatment strategies of type 2 diabetes [J].

Fang, Xinyi ;

Zhang, Yanjiao ;

Huang, Xinyue ;

Miao, Runyu ;

Zhang, Yuxin ;

Tian, Jiaxing .

DIABETES OBESITY & METABOLISM, 2025, 27 (08) :4051-4068

[36] Imo-induced changes in gut hormones and glucose metabolism: A key to improving insulin sensitivity in type 2 diabetes [J].

Naseem, Sobia ;

Rizwan, Muhammad .

DIABETES RESEARCH AND CLINICAL PRACTICE, 2025, 226

[37] Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era [J].

Estrella Martinez-Lopez, Yoscelina ;

Esquivel-Hernandez, Diego A. ;

Paul Sanchez-Castaneda, Jean ;

Neri-Rosario, Daniel ;

Guardado-Mendoza, Rodolfo ;

Resendis-Antonio, Osbaldo .

GUT MICROBES, 2022, 14 (01)

[38] Gut microbiome links obesity to type 2 diabetes: insights from Mendelian randomization [J].

Fu, Li ;

Baranova, Ancha ;

Cao, Hongbao ;

Zhang, Fuquan .

BMC MICROBIOLOGY, 2025, 25 (01)

[39] The Functions of Major Gut Microbiota in Obesity and Type 2 Diabetes [J].

Liu, Siman ;

Tao, Zhipeng ;

Qiao, Mingyu ;

Shi, Limin .

METABOLITES, 2025, 15 (03)

[40] Gut microorganisms as promising targets for the management of type 2 diabetes [J].

Delzenne, Nathalie M. ;

Cani, Patrice D. ;

Everard, Amandine ;

Neyrinck, Audrey M. ;

Bindels, Laure B. .

DIABETOLOGIA, 2015, 58 (10) :2206-2217

← 1 2 3 4 5 →